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Abstract
Background: Rearrangement of the mixed-lineage leukemia gene (MLL) is found in 80% of infant acute
lymphoblastic leukemia (ALL) and is associated with poor prognosis and resistance to glucocorticoids (GCs). We
have recently observed that GC resistance in T-ALL cell lines is associated with a proliferative metabolism and
reduced expression of MLL. In this study we have further explored the relationship between MLL status and GC
sensitivity.
Results: Negative correlation of MLL expression with GC resistance in 15 T-ALL cell lines was confirmed by
quantitative RT-PCR. The absence of MLL-rearrangements suggested that this relationship represented expression of
wild-type MLL. Analysis of MLL expression patterns revealed a negative relationship with cellular metabolism,
proliferation and anti-apoptotic transcriptional networks. In silico analysis of published data demonstrated that
reduced levels of MLL mRNA are associated with relapse and prednisolone resistance in T-ALL patients and adverse
clinical outcome in children with MLL-rearranged ALL. RNAi knockdown of MLL expression in T-ALL cell lines
significantly increased resistance to dexamethasone and gamma irradiation indicating an important role for wild-
type MLL in the control of cellular apoptosis.
Conclusions: The data suggests that reduced expression of wild-type MLL can contribute to GC resistance in ALL
patients both with and without MLL-translocations.
Background
Among pediatric subtypes of acute lymphoblastic leuke-
mia (ALL), infants and those with T-lineage ALL are
particularly resistant to glucocorticoids (GCs), one of
the most important classes of drug for this disease [1].
Rearrangement of the mixed lineage leukemia gene
(MLL) gene affects 80% of ALL in infants and is asso-
ciated with a particularly poor prognosis [2,3]. MLL is
located at 11q23 and encodes a histone methyltransfer-
ase that through its regulation of HOX genes is essential
for normal mammalian development and hematopoiesis
[4]. A unique feature of the MLL l o c u si st h a ti ti ss u b -
ject to an extremely wide variety of rearrangements,
including translocations with >50 partner genes on var-
ious chromosomes, as well as deletions, inversions,
internal duplications and gene amplifications [4-6].
There are conflicting reports on the relative GC
responses of patients with different MLL translocations
[7,8], but those with t(4;11) translocations appear parti-
cularly resistant [3,8,9]. The biological basis for the
documented GC resistance of patients with MLL-disease
has not been explored but has generally been assumed
to be due to the oncogenic effects of translocated MLL
fusion proteins.
Despite the clinical importance of GCs for the treat-
ment of ALL, detailed knowledge about the transduction
pathways leading to GC-induced apoptosis in lymphoid
tissues remains limited [10]. Recently we performed
transcriptional profiling of a panel of T-ALL cell lines
and reported that GC resistance was associated with a
proliferative metabolism [11]. We also observed that GC
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reduced expression of MLL.I nt h i ss t u d yw eh a v e
further investigated the relationship between MLL
expression and GC sensitivity in T-ALL and provide evi-
dence that it is the wild-type expression of the gene,
rather than the effect of translocations, that appears to
be critical for determining a resistant phenotype. This
novel finding may help to explain why GC-resistance is
a common feature of most patients with MLL-disease
despite the wide variety of possible gene rearrangements
Methods
Cell lines and drug sensitivity profiling
The cell line panel has been previously described and
comprised nine T-ALL lines derived in our own labora-
tory from pediatric ALL bone marrow specimens (PER
cell lines), plus six additional T-ALL cell lines obtained
from external sources [12,13]. Cell lines were grown in
RPMI-1640 supplemented with 2 mM L-glutamine, 10
nM 2-mercaptoethanol and 10-20% heat-inactivated
fetal calf serum. The media for PER-cell lines contained
additional non-essential amino acids and pyruvate,
whilst 300 units/ml interleukin-2 is required for growth
of PER-427 and PER-487. The sensitivity of the T-ALL
cell lines to methylprednisolone (MPRED) and dexa-
methasone (DEX) has been previously published [12]
and was measured using the MTT assay with drugs
incubated over four days. The IC50 (drug concentration
that inhibits cell growth by 50%) was used as the mea-
sure of drug resistance.
Gene Expression Profiling
Briefly, RNA was extracted from cell lines in exponential
growth phase and hybridized to Affymetrix HG-U133A
m i c r o a r r a y s[ 1 1 , 1 4 ] .M i c r o a r r a yd a t aw e r en o r m a l i z e d
using robust multi-array analysis (RMA) and all passed
quality control criteria for noise, background, absent/pre-
sent calls, and 3’/5’ signal ratios for ACTB and GAPDH.
To interrogate the biological pathways represented by
MLL expression profiles we used Gene Set Enrichment
Analysis (GSEA) [15]. The median value of the five MLL
probe sets present on the HG-U133A was calculated for
each cell line, and correlated across the panel against all
other probe sets on the array using Pearson’sc o r r e l a t i o n
as metric (GSEA v2.0, May 2006, 10,000 permutations).
GSEA examines ranked lists of genes for enrichment of
biological pathways contained within four different data-
bases: C1 (genomic loci), C2 (curated biological path-
ways), C3 (genes with common regulatory motifs), and
C4 (computational gene networks). Since not all genes
within a given biological pathway are expected to be
regulated in the same direction, rankings were performed
using absolute correlation values as previously described
[11]. Published microarray data used for in silico analysis
[14,16-18] was downloaded from publicly available
depositories or authors’ websites.
Real-time quantitative RT-PCR
Real-time quantitative RT-PCR (qRT-PCR) was per-
formed on total RNA from cell lines in accordance with
standard Applied Biosystems protocols (Foster City, CA)
and in accordance with our published methods [19]. All
experiments were run in duplicates on an ABI 7700
sequence detector and data normalized to expression of
beta-actin (ACTB). Primers and probe for MLL and
GILZ qRT-PCR were purchased from Applied Biosys-
tems (ABI Assays on Demand); the MLL assay targeted
exons 30-31 (Refseq NM_005933).
RNAi knockdown of MLL expression
Three pSM2 retroviral RNAi vectors for MLL
(V2HS_196843, V2HS_198375, V2HS_214961) and a
non-silencing (NS) control vector were obtained from
Open Biosystems (Huntsville, USA). For optimal mam-
malian expression, shRNA inserts were subcloned with
EcoRI and XhoI into MSCV-LMP (MSCV/LTRmiR30-
PIGΔRI, a generous gift from Prof. Scott Lowe, Cold
Spring Harbour Laboratory [20]), which contains GFP
and puromycin selection cassettes and drives miR30-
shRNA expression using the retroviral 5’LTR.
V2HS_198375 (MLL198) was found to suppress MLL
expression most efficiently in transient transfection
e x p e r i m e n t sa n dw a su s e df o rsubsequent experiments.
The retroviral packaging cell line PA317 (selected in
HAT medium) was transfected with linearised miR30-
shRNA plasmid DNA (for both NS control and
MLL198) using Lipofectamine, and GFP-positive cells
were selected with puromycin. Stably transfected retro-
viral-producing PA317 cell lines were g-irradiated (30
Gy) and incubated at 37°C overnight before co-culture
with PER-117 cells for 48 hours. Retrovirally infected
PER-117 cells were subsequently removed and selected
with puromycin to generate cell lines stably expressing
shRNA for MLL (MLL-KD) or the NS control (MLL-
Scr). Efficiency of RNAi knockdown for MLL was
assessed both by qRT-PCR as described above, and by
immunoblot of nuclear protein extracted from cell lines
in log-phase growth using standard methods. Antibodies
used were mouse anti-MLL
C/HRX, clone 9-12 (Upstate
Cell Signaling Solutions, Temecula, CA), which detects
the C-terminal proteolytic fragment of MLL (~180 kDa),
and mouse anti-human b-actin as loading control (Pan
Actin Ab-5 (ACTN05) NeoMarkers, Fremont CA). Den-
sitometric quantitation of protein bands from multiple
extractions taken at independent time points and from
different cell-line stocks was performed using ImageJ
software http://rsbweb.nih.gov/ij/, with MLL expression
normalized to b-actin loading.
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Cell growth and viability were measured using the Vi-
CELL XR Viable Cell Analyzer (Beckman Coulter). Cells
in exponential growth phase were seeded at 5 × 10
5 ml
-1
in a 96-well plate in the presence or absence of dexa-
methasone (10 μg/ml - 258 μg/ml, Mayne Pharma Pty
Ltd, VIC, Australia), 0.025 μg/ml cytarabine (ARAC;
Pharmacia Pty Ltd, NSW, Australia), 0.01 μg/ml metho-
trexate (MTX; David Bull Laboratories), or 1 Gy gamma-
irradiation, and incubated for two days at 37°C before
measuring cell survival. Each drug concentration or con-
dition was tested in triplicate and data were normalised
to values obtained from untreated cells. For metabolic
assays, cells in exponential growth were seeded at 5 × 10
5
ml
-1 in fresh media and incubated for two days at 37°C
before harvesting supernatants. Glucose and lactate
supernatant concentrations were measured using the
Amplex Red kit (Invitrogen, Australia), substituting lac-
tate oxidase (Sigma, Australia) as required. For assess-
ment of GILZ induction, MLL-KD and MLL-Scr cells in
exponential growth were incubated with 1 μMd e x a -
methasone (Mayne Pharma Pty Ltd, VIC, Australia) for
four hours prior to RNA extraction and measurement by
qRT-PCR.
Results
MLL mRNA Expression and GC resistance in T-ALL Cell
Lines
Our laboratory has developed an authenticated panel of
pediatric T-ALL cell lines that have been grown in the
absence of drug selection. These cultures retain critical
features of the primary disease and their drug resistance
profile parallels the spectrum of resistance that has been
observed in primary patient specimens [12]. We recently
examined the baseline resistance of these 15 T-ALL cell
lines to the GCs DEX and MPRED [12] and correlated
the data with gene expression profiles as determined by
HG-U133A microarray [11]. Although these lines have
been cultured without prior exposure to in vitro drug
selection pressure they demonstrate a natural spectrum
of GC resistance, with IC50 values across the panel
varying by 4-5 orders of magnitude (Figure 1A). This
resistance profile is not explained by mutations in the
glucocorticoid receptor (GR) or variations in its level of
expression [21], indicating that defects downstream of
the GR are primarily responsible for GC resistant phe-
notypes in these cell lines.
Our analysis of the microarray data revealed that GC
resistance was significantly correlated with reduced
expression of MLL [11]. To confirm this correlation we
used qRT-PCR to measure MLL mRNA expression
across the panel, using a probe targeting the 3’ end of
the MLL coding region. Expression levels measured by
qRT-PCR were highly correlated with resistance to both
GCs (Figure 1A; correlation vs. dexamethasone IC50
-0.849 (p < 0.0001), methylprednisolone IC50 -0.851 (p
< 0.0001)). Whilst translocations of the MLL gene are
prevalent in infant ALL they are infrequent in T-ALL
[8,9,22], suggesting that the observed correlation
reflected expression of the wild-type gene. Indeed, T-
ALL cell line karyotypes indicated no abnormalities at
the 11q23 MLL-locus [12], a conclusion confirmed by
Southern Blot for all 15 cell lines (data not shown). On
the HG-U133A microarray there are five independent
probes for MLL, and these span the entire length of the
gene, encompassing both sides of the major break
region (MBR) that is involved in almost all translocation
events (Figure 1B). Across the 15 T-ALL cell lines cor-
relation of MLL mRNA expression and GC resistance
was significant for all five probe sets (median probe sig-
nificance DEX p = 0.0025, MPRED p < 0.0001) indicat-
ing no discrepancy in expression between the 5’ and 3’
regions of the gene. Based on these data we conclude
that the observed correlation with GC sensitivity in T-
ALL cell lines is related to expression levels of wild-type
MLL rather than MLL-translocation products.
Biological features of MLL expression in T-ALL
To gain further insight into the transcriptional programs
associated with MLL, the expression profile of this gene
across the T-ALL cell line panel was correlated to the
expression of all other genes on the microarray. This
output was analyzed with GSEA to identify the biologi-
cal networks associated with variations in MLL expres-
sion. The strongest signatures were returned from the
C2 (curated pathway) and C4 (computational gene net-
work) databases, with 17 and 83 enriched gene sets
respectively falling within the significant GSEA false dis-
covery rate (FDR). Very few significantly enriched gene
sets were identified from genomic loci and regulatory-
motif databases (C1 and C3). The top ranked significant
gene sets from the C2 and C4 databases are listed in
Tables 1 &2. The majority of these pathways are
involved with the control of cell growth and metabolism
(e.g. MYC-regulated pathways, RNA transcription, oxi-
dative phosphorylation, the TCA cycle, proteasomal reg-
ulation, nucleotide synthesis, translation initiation and
antioxidant defense). The overwhelming direction of
expression of these pathways was a negative correlation
with expression of MLL. Thus lower expression of MLL
in these cell lines is associated with signatures consistent
with a proliferative phenotype. In addition the expres-
sion levels measured by each of the five MLL probe sets
were found to correlate significantly with cell line dou-
bling times [12] (median correlation 0.67, p < 0.01).
These findings are in keeping with our previous obser-
vation that reduced expression of MLL is part of a pro-
liferative metabolism signature that is associated with
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Page 3 of 13Figure 1 Relationship between MLL expression and GC resistance in T-ALL Cell Lines. (A) Normalized MLL mRNA expression across the T-
ALL cell line panel as measured by qRT-PCR (bars) and IC50 values for MPRED (open circles) and DEX (closed squares); (B) Schematic of MLL
mRNA indicating the target location of five microarray probes (indicated by solid lines) and protein domains within the coding region: MBR,
Major Break Region; RD, Repression Domain; TAD, Transactivation Domain; PC, site of proteolytic cleavage. Correlation of expression level vs. cell
line IC50 for DEX (D) and MPRED (M) is indicated for each probe (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
Table 1 Top ranked GSEA gene sets from the C2 database (curated pathways) associated with MLL expression profiles
in T-ALL cell lines
Gene Set Description of Biological Pathway FDR *
Electron_transport_chain Electron transport chain 0.137
Glycolysis_gluconeogenesis Glycolysis and gluconeogenesis 0.142
Peng_leucine_down Down-regulated in response to leucine starvation 0.145
RNA_transcription_reactome RNA transcription reactome 0.145
Mitochondria Mitochondrial genes 0.148
Aminoacyl_tRNA_biosynthesis Amino-acyl tRNA biosynthesis 0.151
Human_mitodb_6_2002 Mitochondrial genes 0.152
Hdaci_colon_cur24hrs_up Genes upregulated by curcumin, transcription inhibitor 0.156
Hdaci_colon_cur48hrs_up Genes upregulated by curcumin, transcription inhibitor 0.163
Myc_huvec_sage_array_up Genes up-regulated by myc 0.176
Peng_rapamycin_down Down-regulated in response to rapamycin 0.183
Oxidative_phosphorylation Oxidative phosphorylation 0.190
tRNA_synthetases tRNA synthetases 0.192
Proteasome_pathway Proteasomal pathway genes 0.200
Peng_glutamine_down Down-regulated in response to glutamine starvation 0.203
Krebs_TCA_cycle Krebs (TCA) cycle genes 0.204
Proteasome Proteasome genes 0.238
* FDR, false discovery rate; GSEA cutoff for significance FDR <0.25.
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eral gene sets were involved with the regulation of apop-
tosis (MORF_AATF, MORF_MAPK2), p53 response
(MORF_EI24, GNF2_NS) and DNA damage repair
(MORF_UNG), with the direction of association linking
reduced MLL-expression with the activation of anti-
apoptotic transcriptional networks (Table 2).
MLL-Translocation Partner Genes Correlate with MLL
Expression
Recent evidence suggests that the genes most commonly
translocated with MLL are not selected at random but
may in fact be functionally related as part of an ‘MLL-
web’ [5,23,24]. If this is true, then in the context of the
observed relationship between MLL expression and GC
resistance in the present study (Figure 1A) one might
predict that the expression of these genes would simi-
larly be correlated with GC resistance in our T-ALL cell
lines. Of the >50 known translocation partner genes of
MLL, 43 are represented on the HG-U133A microarray
(corresponding to a total of 93 probe sets). Despite the
absence of MLL-translocations in the T-ALL cell lines
we observed that a large number of these (18 genes, 26
probe sets) were significantly correlated to MPRED and
DEX resistance (Table 3). This association is much
greater than would be predicted by chance alone (exact
binomial test, p < 0.001). It is relevant that the majority
of the genes listed in Table 3 are involved in transcrip-
tional regulation (GMPS, DCPS, ELL, LPP, AF10,
CREBBP, EP300, AF4), proliferation (GAS7) or metabo-
lism (CBL, GPHN and ACACA, the latter being the rate
limiting enzyme for conversion of acetyl-coA into cho-
lesterol). The correlation of these genes with GC resis-
tance may therefore be reflective of the metabolic and
proliferative changes driving this phenotype in T-ALL
cell lines of which MLL appears to be a part [11].
Reduced MLL Expression in T-ALL Patients is Associated
with GC Resistance and Relapse
Since our data indicated an association between GC sen-
sitivity and expression levels of MLL in T-ALL in vitro
we looked for further evidence in the literature for such
an association. Holleman et al previously examined the
ex vivo sensitivity of diagnostic pediatric ALL patient
specimens to individual induction therapy agents and
correlated the findings with gene expression data mea-
sured in the same samples using HG-U133A Affymetrix
microarrays [17]. We examined this data for the expres-
sion level of MLL in T-ALL patient specimens from this
cohort that were determined to be sensitive or resistant
to prednisolone. Importantly, three of the five MLL
probe sets on the array showed a significantly lower
Table 2 Top ranked GSEA gene sets from the C4 database (computed gene networks) associated with MLL expression
profiles in T-ALL cell lines
Gene Set Description of Network Hub Genes and Associated Functions FDR *
MORF_PRDX3 Peroxiredoxin 3 - MYC-mediated proliferation, glucose responses 0.132
MORF_SOD1 Superoxide dismutase 1 - mitochondria, oxidative metabolism 0.135
MORF_MAP2K2 MAP2K2 - ERK, JNK, p38, NFkB, and apoptosis pathways 0.138
MORF_PTPN11 Protein tyrosine phosphatase, cell growth, differentiation, metabolism 0.140
GNF2_RAN RAS oncogene family - cell cycle, mitotic spindle regulation 0.143
MORF_GMPS Guanine monphosphate synthetase - purine synthesis, cell cycle 0.146
MORF_DEAF1 DEAF1 or supressin, inhibitor of proliferation 0.152
MORF_ERH Enhancer of rudimentary homolog - cell cycle regulator 0.155
GNF2_NS Nucleostemin - cell cycle progression in stem cells, links with p53 0.158
MORF_GPX4 Glutathione peroxidase 4 - cellular antioxidant defence 0.159
MORF_AATF Apoptosis antagonizing transcription factor 0.160
MORF_EIF3S2 EIF3S2 - eukaryotic translation initiation factor 0.164
MORF_ATOX1 ATX1 antioxidant protein 1 homolog - antioxidant defense 0.165
MORF_EI24 Etoposide induced mRNA - early p53 response gene 0.166
MORF_PSMC1 Proteasome 26S subunit, ATPase 0.173
MORF_RAN RAS oncogene family - cell cycle, mitotic spindle regulation 0.179
MORF_RAB5A Ras-associated protein - exocytosis, actin organisation 0.180
MORF_UNG Uracil-DNA glycosylase - base-excision DNA repair pathway 0.182
MORF_FBL Fibrillarin - component of snRNP synthesis of ribosomal RNA 0.203
GCM_MAX Myc-associated factor X - transcriptional regulator 0.224
* FDR, false discovery rate; GSEA cutoff for significance FDR <0.25.
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association we observed in T-ALL cell lines. Figure 2A
shows the data for the probe set with the strongest asso-
ciation (212079_s_at, p < 0.001 unpaired t-test), and for
the summary of the five probe sets calculated using
median expression values (p < 0.05, unpaired t-test). For
further evidence of a link between MLL expression and
GC resistance we examined a dataset we have previously
published comparing gene expression patterns in pedia-
tric ALL specimens taken at the time of diagnosis and
relapse [14]. Although we were not able to directly mea-
sure the GC sensitivity of these specimens it is known
that almost all patients initially respond to induction
therapy and achieve first remission, whilst GC resistance
is a well-documented feature of relapse [25,26]. It is
therefore reasonable to expect that many of the relapse
specimens in this cohort would have elevated GC resis-
tance compared to their diagnostic counterparts. Exam-
ining the same MLL probe sets as above, we observed a
decrease in MLL expression in T-ALL relapse specimens
vs. diagnosis specimens (Figure 2B) comparable to that
measurable in GC resistant vs. sensitive specimens [17]
(Figure 2A). This differential was only statistically signif-
icant for probe set 212079_s_at (p < 0.001, unpaired
t-test), but the same trend was visible for the other four
probe sets and is reflected in the summary of the med-
ian expression values for all five probes (Figure 2B).
Since both of these studies involve T-ALL patients it is
likely that the majority of patients within these cohorts
do not have rearrangements affecting MLL.T a k e n
together, this data provides clear support from two inde-
pendent data sets that the correlation we have observed
between wild-type MLL expression and GC sensitivity in
T-ALL in vitro appears to also be relevant in vivo.
Relevance of MLL Expression Level in Patients with MLL-
Disease
In our T-ALL cell lines we observed a 35-fold variation
in MLL expression across the panel that correlated with
GC resistance (Figure 1A). To assess the degree with
which endogenous MLL expression levels vary in pri-
mary ALL patient specimens we analyzed data published
by Ross et al who performed gene expression profiling
of pediatric ALL subtypes [18]. Figure 3A shows that of
Table 3 MLL Translocation Partner Genes Significantly Correlated with GC IC50 in T-ALL Cell Lines
Probe Set Gene Title Symbol Chr MPRED DEX*
220773_s_at Gephyrin GPHN 14q23.3 0.915 0.670
212186_at Acetyl-CoA carboxylase alpha ACACA 17q21 0.767 0.558
214431_at Guanine monphosphate synthetase GMPS 3q24 0.754 0.505
218774_at Decapping enzyme, scavenger DCPS 11q24.2 0.637 0.744
204096_s_at Elongation factor RNA pol II ELL 19p13.1 0.581 0.779
202821_s_at LIM domain containing preferred translocation partner in lipoma LPP 3q28 0.577 0.418
214358_at Acetyl-CoA carboxylase alpha ACACA 17q21 0.569 0.197
216506_x_at MLL (trithorax homolog, Drosophila); translocated to, 10 MLLT10/AF10 10p12 0.560 0.293
200713_s_at Microtubule-associated protein, RP/EB family, member 1 MAPRE1 20q11.1-11.23 0.560 0.542
211808_s_at CREB binding protein (Rubinstein-Taybi syndrome) CREBBP 16p13.3 0.558 0.470
215578_at Gephyrin GPHN 14q23.3 0.526 0.473
209768_s_at SEPT5 SEPT5/PNUTL 22q11.21 0.519 0.229
216503_s_at MLL (trithorax homolog, Drosophila); translocated to, 10 MLLT10/AF10 10p12 0.516 0.307
211067_s_at Growth arrest-specific 7 GAS7 17p13.1 -0.300 -0.541
210872_x_at Growth arrest-specific 7 GAS7 17p13.1 -0.334 -0.580
202191_s_at Growth arrest-specific 7 GAS7 17p13.1 -0.385 -0.624
202192_s_at Growth arrest-specific 7 GAS7 17p13.1 -0.417 -0.589
202221_s_at E1A binding protein p300 EP300 22q13.2 -0.542 -0.315
212288_at Formin binding protein 1 FNBP1 9q34 -0.575 -0.624
209027_s_at Abl-interactor 1 ABI1 10p11.2 -0.580 -0.417
205068_s_at Rho GTPase activating protein 26 ARHGAP26 5q31 -0.607 -0.661
209028_s_at Abl-interactor 1 ABI1 10p11.2 -0.608 -0.472
214298_x_at Septin 6 SEPT6 Xq24 -0.615 -0.386
201924_at MLLT2 MLLT2/AF4 4q21 -0.660 -0.671
206607_at Cas-Br-M (murine) ecotropic retroviral transforming sequence CBL 11q23.3 -0.681 -0.456
213579_s_at E1A binding protein p300 EP300 22q13.2 -0.742 -0.404
* Correlation coefficient (r) of probe set expression with MPRED or DEX IC50 values; Chr, chromosomal locus; bold values, p < 0.05. Genes are grouped together
by positive (top) or negative correlation (bottom).
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Page 6 of 13all the pediatric ALL subtypes, the widest variations in
MLL expression levels are found in patients with T-line-
age ALL and those with MLL-rearrangements. To exam-
ine the prognostic relevance of MLL expression
variation in patients with MLL- d i s e a s ew ee x a m i n e da
publication describing the use of Affymetrix HG-U95v2
microarrays to examine gene expression patterns in ALL
patients with MLL-rearrangements [16]. These authors
reported that such patients could be clustered on the
basis of their genome-wide transcriptional profile into
two distinct subgroups (called A and B) that demon-
strated dramatically different survival rates (Figure 3B,
box, p = 0.0005). By analyzing the data from their study
we have ascertained that the expression of MLL was sig-
nificantly lower in poor-outcome patients (Group A)
compared to those with good outcome (Figure 3B, bar
chart, p = 0.008). The HG-U95v2 probe for MLL targets
the 3’ UTR of the gene, meaning that it would either
detect expression of the full-length (non-translocated)
MLL allele remaining in these patients, or the expres-
sion of any reciprocal fusion that was transcribed as far
as this 3’ probe. Certainly it would not detect signal
from primary MLL-translocation products. While the
authors did not experimentally determine GC sensitivity
in their study [16], the data are consistent with the
hypothesis that the level of wild-type MLL expression is
linked to therapeutic outcome even in patients that have
an MLL-translocation on the alternate allele.
MLL Knockdown Increases Resistance to GC Exposure and
DNA Damage
To assess the role of wild-type MLL in GC resistance phe-
notypes we used a retroviral RNAi expression system in
the PER-117 T-ALL cell line to generate cell lines stably
expressing shRNA for MLL (MLL-KD) or a non-silencing
shRNA scrambled control (MLL-Scr). MLL mRNA
expression in MLL-KD cells was 69% lower on average
than in MLL-Scr control cells as assessed by qRT-PCR
(Figure 4A, p < 0.0001). This correlated to a ~20% reduc-
tion in MLL nuclear protein as assessed by immunoblot
(Figures 4B and 4C, p < 0.05). Proliferation assays demon-
strated that MLL-KD cells grew approximately 10% faster
on average than MLL-Scr cells (Figure 4D, p < 0.05
ANOVA). To assess GC sensitivity in the two lines, cell
viability was assessed after a two-day incubation with dex-
amethasone (Figure 4E). MLL-KD demonstrated increased
viability compared to MLL-Scr cells at all doses tested (p <
0.05, two-way ANOVA) indicating GC resistance. To
assess the specificity of this protective effect we examined
the sensitivity of the cells to gamma-irradiation, and
Figure 2 Reduced MLL expression is associated with GC resistance and relapse in T-ALL patients. Published HG-U133A microarray
datasets were examined for the expression of MLL using either a single probe (212079_s_at) or the median of all five MLL probe sets on the
array. Data represent the mean ± SEM (linear scale) of the indicated patient numbers (n). (A) Difference in MLL expression in pediatric T-ALL
patient specimens with ex vivo sensitivity or resistance to prednisolone [17]; (B) Difference in MLL expression in pediatric T-ALL patient specimens
measured at diagnosis or relapse [14].
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(MTX). Interestingly, MLL-KD cells showed greater survi-
val following gamma-irradiation indicating resistance to
DNA damage (Figure 5A, p < 0.05 unpaired t-test). Resis-
t a n c et oA R A Ca n dM T Xh o w e v e rw a sn o ts i g n i f i c a n t l y
different between the two cell lines. The proportion of
dying (necrotic) cells after two days was significantly
reduced in MLL-KD cells in response to both dexametha-
sone and gamma-irradiation, indicating a cytoprotective
effect of MLL knockdown (Figure 5B). Baseline viability in
untreated cells was not significantly different between the
cell lines.
To assess the effects of MLL knockdown on cell meta-
bolism we compared rates of glucose consumption and
lactate production between the two cell lines. Consistent
with an increased rate of proliferation MLL-KD cells
demonstrated an increased rate of glucose consumption
compared to control cells. This was accompanied by a
decreased rate of lactate production, resulting in a sig-
nificant drop in the lactate production:glucose consump-
tion ratio in MLL-KD cells (Figure 5C). Finally, since
MLL is known to be a master transcriptional regulator
we assessed whether the GC resistant phenotype of
MLL-KD cells might represent transcriptional suppres-
sion of GC response elements by measuring the induc-
tion of GILZ, a well-characterized GC-response gene,
following incubation with dexamethasone. There was no
significant difference in the induction of GILZ mRNA
between MLL-KD and MLL-Scr cell lines following a 4
hour incubation with dexamethasone (Figure 5D), indi-
cating that GC-transcriptional responses in MLL-KD
cells appeared to be intact.
Figure 3 MLL expression patterns in patients with MLL-disease. (A) Box and whisker plot of published microarray data [18] showing the
variation of MLL expression in different ALL subgroups (HG-U133Plus2 probe 212076_at); (B) Analysis of published microarray data from ALL
patients with MLL-rearrangements [16]. This study described two clusters of patients (A and B) with significantly different survival rates (boxed
data) and expression of MLL (graph, mean ± SEM).
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Although there are conflicting reports of the effect of
MLL-rearrangements on steroid resistance [7,8], it is clear
that all infants with MLL-rearrangements have signifi-
cantly worse prognosis than those with non-rearranged
MLL regardless of the type of translocation involved
[3,27]. However, the present study has been conducted
using T-ALL cell lines without MLL-translocations and
provides evidence that in the absence of such transloca-
tions cellular GC sensitivity is related to the level of
expression of wild-type MLL. One interpretation of this
data is that alterations in MLL support the proliferative
p h e n o t y p et h a tw eh a v ep r e v i o u s l ya s s o c i a t e dw i t hG C
resistance [11]. In lymphocytes, GCs are thought to trigger
a metabolic crisis that ultimately leads to apoptosis [28].
In addition to suppressing apoptotic potential through
the modulation of mitochondrial energetics, up-regulation
of biosynthetic and metabolic pathways to support
proliferation may therefore confer GC resistance by offset-
ting the adverse metabolic consequences of GC signalling
[11]. MLL has recently been shown to be important for
the control of cell proliferation but the mechanism is com-
plex, involving a bimodal pattern of expression throughout
the cell cycle [29]. In our experiments, suppression of MLL
was associated with a small increase in proliferation and
glucose consumption but decreased lactate production,
indicating a shift away from aerobic glycolysis to alterna-
tive pathways, such as oxidative phosphorylation or the
pentose-phosphate shunt. Besides energy production,
these pathways are essential for the synthesis of macromo-
lecules, nucleotides and nucleic acids required for prolif-
eration [30].
In addition to elevated GC resistance, knockdown of
MLL expression was associated with increased resistance
to gamma-irradiation indicating an unexpected protec-
tion from the effects of DNA-damage. Recently it has
Figure 4 Effect of MLL knockdown on proliferation and sensitivity to dexamethasone. (A) Level of stable MLL mRNA knockdown in MLL-
KD cells as measured by qRT-PCR compared to MLL-Scr cells expressing non-silencing scrambled shRNA; (B) Reduction of MLL nuclear protein
expression in MLL-KD cells as assessed by immunoblot detection of the MLL
C proteolytic fragment from four independent extractions and
normalized to b-actin loading control; (C) Representative immunoblot of nuclear MLL
C (~180 kD, top panel) and b-actin (42 kD, bottom panel)
protein expression in MLL-Scr and MLL-KD cell lines; (D) Proliferation of MLL-Scr and MLL-KD cell lines over four days; (E) Differential growth of
MLL-Scr and MLL-KD cells over two days in the presence of dexamethasone; In each case (A-B, D-E) data represent mean ± SEM from 3-6
independent experiments; Statistical analysis was by t-test (A, B) or ANOVA (D, E); * p < 0.05, *** p < 0.001.
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methyltransferases are critical components of an E2F1-
signalling pathway that mediates links cell cycle control
to DNA damage responses, and that their knockdown
attenuates the apoptotic response to adriamycin [31].
This highlights the tumor suppressor role of these pro-
teins and is consistent with the protection from DNA-
damage we have observed following MLL-knockdown in
T-ALL cell lines. In contrast however, no protective
effect of MLL-knockdown was seen for ARAC or MTX
in the present study. Whilst one might expect that sup-
pression of DNA-damage response pathways should
increase resistance to both of these agents, it is interest-
ing to note that, unlike GCs, elevated resistance to
neither of these drugs is associated with MLL-
rearrangement [32,33]; infants in fact are known to be
generally more sensitive to ARAC [8,32]. There may
therefore be some unexplained insult specificity in the
role of MLL in mediating responses to DNA-damage.
Across the T-ALL cell lines there was a 35-fold varia-
tion in the level of MLL-expression. Surprisingly the
mechanisms controlling expression of wild-type MLL
have not been extensively studied, with most work
focusing on the downstream effects of the gene and its
various fusion products. However the putative MLL pro-
moter has binding motifs for a large number of tran-
scription factors, including SREBF1 (sterol regulatory
element binding transcription factor) and MYC. MYC is
a pivotal player in the control of cell cycle and apoptosis
[34], is one of the known downstream targets of GC
Figure 5 Effect of MLL knockdown on cellular resistance, metabolism and GC signaling. (A) Effect of gamma-irradiation (g- I R ,1G y ) ,
methotrexate (MTX, 0.01 μg/ml), cytarabine (ARAC, 0.025 μg/ml) on growth of MLL-Scr and MLL-KD cell lines over two days; (B) Percentage of
dying or necrotic cells (normalized to untreated) in MLL-Scr and MLL-KD after 48 hours in the presence of dexamethasone (DEX, 250 μM or 500
μM) or following gamma-irradiation (g-IR, 1 Gy); (C) Ratio of lactate production/glucose consumption over two days in MLL-Scr and MLL-KD cells;
(D) Relative expression of GILZ mRNA as measured by qRT-PCR in MLL-Scr and MLL-KD cell lines incubated for four hours in the absence (-) or
presence (+) of dexamethasone (1 μM); In each case (A-D) data represent mean ± SEM from 3-6 independent experiments with statistical
analysis by unpaired t-test; * p < 0.05, ** p < 0.01.
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be up-regulated in MLL-disease [36]. MLL expression is
also likely to be subject to miRNA control, with numer-
ous miRNA binding sites predicted to reside in the MLL
3’UTR. Although downstream effects of MLL or MLL-
translocations on miRNA expression has been reported
by a number of groups, to our knowledge only one
recent study has reported the upstream miRNA regula-
tion of MLL itself [37]. In that study ectopic expression
of mirR-221 and miR128 was shown to affect levels of
MLL, MLL-fusions and GC sensitivity in ALL cell lines
[37], consistent with the hypothesis that levels of MLL
expression are important for GC resistance. It remains
to be seen whether the observed effects of miRNA ecto-
pic expression on GC sensitivity were due to effects on
MLL-fusion proteins or endogenous wild-type MLL and
the hierarchy for these mechanisms therefore remains to
be untangled.
How do the present findings, performed in T-ALL
with no MLL-translocations, relate to patients with
MLL-disease? Although loss-of heterozygosity (LOH) at
the MLL locus has been reported to be a relatively
frequent event in childhood ALL, consistent with a
potential role as a tumor suppressor [38], this is not the
case in patients with MLL-disease where one wild-type
copy of MLL appears to be retained [38-40]. This indi-
cates that allele loss and MLL-translocation are mutually
exclusive oncogenic events, but little focus has been
given to the regulation of the remaining wild-type allele
following translocation. However Whitman et al have
recently demonstrated that in myeloid leukemia MLL
partial tandem duplications (PTD) are associated with
silencing of the wild-type MLL copy through an autore-
gulatory mechanism involving altered methylation [41].
Interestingly, in one MLL-PTD patient wild-type MLL
was expressed at diagnosis but absent at relapse, sug-
gesting a correlation with disease progression. Wild-type
MLL expression could be re-induced in primary blasts
with the use of DNA methyltransferase (DNMT) or
histone deacetylase (HDAC) inhibitors, or suppression of
the MLL-PTD transcript, and was associated with
increased apoptotic sensitivity and reduced colony-
forming capability. Other workers have recently demon-
strated down-regulation of wild-type MLL in myeloid
leukemia patients with different types of rearranged-
MLL [42] suggesting that it may be a common feature
of MLL-related leukemia.
Conclusions
Based on the evidence presented we hypothesize that
GC resistance in patients with MLL-disease may partly
result from decreased expression and tumor suppressive
effects of wild-type MLL, either through a gene-dosage
effect following the functional loss of one allele via
translocation, auto-regulation from the MLL-fusion pro-
tein, or altered miRNA/transcription factor signaling.
This would help to explain why GC-resistance is a com-
mon feature of most patients with MLL-disease despite
t h ew i d ev a r i e t yo fp o s s i b l eg e n er e a r r a n g e m e n t s .
Amplifications of the MLL gene do occur but are much
more rare. To our knowledge only one report exists
where such a patient has been tested for ex vivo GC
sensitivity [43] - in that small study a single patient with
MLL amplification demonstrated GC sensitivity whilst
all patients with MLL deletions or rearrangements
demonstrated GC resistance, observations entirely con-
sistent with our hypothesis.
We do not propose that the MLL-translocation event
itself is without oncogenic effects since this has been
clearly demonstrated by other workers, but rather that
our data may help to explain the poor-response to ther-
apy in this disease. Neither do our findings negate the
possibility that MLL-fusion proteins themselves may
have additional effects upon apoptotic sensitivity.
Indeed, recent experiments have shown that multiple
MLL-fusion proteins inhibit p53 and confer resistance
to DNA damage [44]. However, it is important to note
that in these experiments fusion protein constructs were
ectopically expressed into cell lines containing wild-type
MLL. In view of the evidence discussed here it would be
important to know whether expression of endogenous
MLL was altered during these experiments and whether
this contributed to the observed anti-apoptotic effects.
Increased resistance to DNA damage-induced apoptosis
h a sb e e np r o p o s e da sap h e n o t y p eo fMLL-disease that
explains the short latency associated with disease emer-
gence [45]. It is possible that this effect could originate
from the loss of tumor suppressor function of the wild-
type MLL as well as from direct anti-apoptotic effects of
the fusion protein.
During the preparation of this manuscript Liu et al
[46] published a report describing a role for wild-type
MLL in the maintenance of genome integrity through
the regulation of the S-phase cell cycle checkpoint.
DNA synthesis in cells deficient in wild-type MLL was
found to be resistant to ionizing radiation and a range
of DNA-damaging agents, supporting a role for wild-
type MLL in the mediation of cellular DNA damage
responses [46]. Under this model, MLL-fusion proteins
acted as dominant negative mutants to abrogate the
ATR-mediated stabilization of wild-type MLL reported
to occur in response to DNA damage. The findings are
in keeping with those from the present study and sup-
port our conclusion that reduced levels of wild-type
MLL can contribute to increased cellular resistance even
in the absence of an MLL-translocation event.
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